The CSL Behring Commitment
CSL Behring is passionate about safety, quality and the consumers we serve. Our extensive research and development and range of support services demonstrate our ongoing commitment to all who count on our products. We are deeply committed to providing the best possible therapies and services.

CSL Behring demonstrates its commitment to patients in many ways. Among other things, we sponsor programs and support the patient organizations that benefit people with primary immune deficiencies.

CSL Behring’s resources and services help consumers and families manage the daily challenges of living with a chronic disorder. CSL Behring operates Web sites that provide disease and product information. For example, in some countries, you can use the Web site to reach a patient with hemophilia in order to ask questions or to offer or obtain emotional support. CSL Behring works closely with patient groups on a range of issues from education to advocacy. We work with legislators and regulators around the world to assure patient access and appropriate reimbursement for high-quality and safe plasma-derived and recombinant products.

CSL Behring is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan. CSL Behring is working with the Plasma Protein Therapeutics Association and EFPIA Japan to develop a system that will allow simultaneous new drug submissions in Japan, Europe and the United States. What’s more, these policy groups are trying to persuade the Japanese government to establish a more rational and easy-to-access process for reimbursement pricing. In the United States, CSL Behring has programs to help ensure that people who rely on our therapies can continue to receive these vital treatments during lapses in their health insurance.

Next: Talking With My Nurse or Doctor